Scientists are developing a new “smart capsule” that could deliver medications directly to the large intestines.
“Usually, when you take medication it is absorbed in the stomach and small intestine before making it to the large intestine,” says Babak Ziaie, a professor of electrical and computer engineering at Purdue University. “However, there are many medications that you would like to deliver specifically to the large intestine, and a smart capsule is an ideal targeted-delivery vehicle for this.”
Such an innovation might be used to treat of irritable bowel syndrome, Crohn’s disease, and a potentially life-threatening bacterial infection called Clostridium difficile in which the body loses natural microorganisms needed to fight infection.
People are sometimes treated for C. difficile by transplanting feces from another person into the patient’s large intestine, which provides vital microbes. However, it might be possible to convert the microbes into a powder through freeze-drying and deliver them with smart capsules instead, Ziaie says.
Researchers tested the smart capsule with a “fluidic model” that mimics the gastrointestinal tract and also using an experiment that recreates the changing acidity and peristalsis of the stomach and intestines as food passes through the digestive system.
“It takes up to 12 hours to get to the large intestine, so we wanted to make sure the smart capsule can withstand conditions in the gastrointestinal tract,” Ziaie says.
A capacitor, charged before use, powers the capsule. A switch inside the capsule is activated by a magnet that could be worn on the patient’s waist. As the capsule meanders through the intestines it eventually comes close to the magnet, activating the switch and releasing a spring-loaded mechanism that opens the capsule, which delivers the medication.
The prototype capsule is about the same size as a 000-size gelatin capsule and is designed to release the powdered medication just before reaching the ileocecal valve, where the small and large intestines meet.
Findings appear online in the Institute of Electrical and Electronics Engineers (IEEE) Transactions on Biomedical Engineering.
The researchers have filed a provisional US patent application through Purdue’s Office of Technology Commercialization of the Purdue Research Foundation.
The research is ongoing and is based at Purdue’s Birck Nanotechnology Center. Future work may involve human patients.
Source: Purdue University